Tumor immune studies and tailored co-culture
Tumor immune co-culture & TME profiling
Design co-culture and multimodal assays around tumor cells, the sample’s immune-cell context and treatment response.
PDO 2.0 immune evidence
Observe tumor tissue and immune response
A ccRCC study shows tissue imaging and ICB-related flow results; a separate NSCLC study shows CD4/CD8 counts under IL-2 conditions. Endpoints are selected for the sample’s immune baseline and candidate mechanism.
View imageTissue and model context: PanCK, CD3 and DAPI imaging compares tumor-epithelial and CD3-positive immune-cell signals across the source tissue and PDO culture time points.
TRiCBIO ccRCC PDO 2.0 immune-context study dataView the TME study
View imageChanges after immune-checkpoint blockade: flow cytometry measures PD-L1, CD8, CD56, early apoptosis and necrosis to compare immune profiles and cell death across treatment conditions.
TRiCBIO ccRCC PDO 2.0 immune-context study dataView the TME study
View imageT-cell analysis in NSCLC PDO 2.0: CD4/CD8 counts within CD3-positive tumor-infiltrating lymphocytes are compared across IL-2 conditions. LC-1 to LC-4 were assessed at day 7 and LC-5 at day 28.
TRiCBIO NSCLC PDO 2.0 study dataView the lung cancer PDO 2.0 studyStudy applications
When TME readouts matter
Compare immunotherapy or combination conditions
Integrate tissue, cellular and secreted readouts
Study workflow
Define immune context before treatment
Sample and immune baseline
Define tumor type, sample state, measurable immune components and the program priority.
Select PDO 2.0 or co-culture
Choose ALI, custom co-culture or a combined study design based on architecture, immune context and assay platform.
Treatment and multimodal readouts
Select histology, flow, cytokines, apoptosis or TCR profiling around the candidate mechanism.
Interpret multidimensional results
Interpret tumor-cell change, immune-population shifts and sample context together in relation to the study objective.
Deliverables
Receive integrated tissue, immune and treatment-response results
- Model and immune-baseline QC
- Tissue imaging, flow or secreted-factor data
- Analytical methods, interpretation and study scope
Related models
Select the model by biological context
At study start, we confirm the sample immune baseline, culture window and measurable endpoints, then tailor co-culture, TME assays and orthogonal validation to the study.
PROJECT DISCUSSION
Plan a tumor-immune and TME study
Describe the tumor type, sample or immune-cell context, candidate mechanism and immune changes of interest. Our scientists will configure the model, controls and multimodal assays.